Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sorafenib + oxaliplatin + fluorouracil
- Development stage
- Phase 2
- Lead developer
- Peking University
- Modality
- Small Molecules
- Administration
- Oral, Intra-arterial
01
Overview
This combination regimen consists of the oral multikinase inhibitor sorafenib and hepatic arterial infusion chemotherapy (HAIC) using oxaliplatin and 5-fluorouracil (5-FU). It was evaluated in a Phase 2 clinical trial led by Peking University for the treatment of hepatocellular carcinoma (HCC) with major portal vein tumor thrombosis (PVTT). Sorafenib acts by inhibiting tumor angiogenesis and proliferation through the blockade of VEGFR, PDGFR, and the RAF/MEK/ERK pathway. Oxaliplatin is a platinum-based agent that causes DNA cross-linking, while 5-fluorouracil is an antimetabolite that inhibits thymidylate synthase, interfering with DNA synthesis. The HAIC delivery method allows for high local concentrations of chemotherapy within the liver while reducing systemic side effects.
- Brand names
- Nexavar
- Other names
- HAIC-FO + sorafenibSorafenib plus HAIC (oxaliplatin and 5-fluorouracil)Sorafenib plus HAIC with Oxaliplatin and Fluorouracil
02
Targets
DNAPDGFR (PDGFR family)KIT (c-KIT proto-oncogene receptor tyrosine kinase)RAF1 (c-Raf-1 (Y340D/Y341D))FLT3 (Fms related receptor tyrosine kinase 3)TS (Thymidylate synthase)VEGFR (VEGFR family)
Beyond the preview
Go deeper on sorafenib + oxaliplatin + fluorouracil.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sorafenib + oxaliplatin + fluorouracil.